AUSTIN, Texas--(BUSINESS WIRE)--Babson Diagnostics™, a science-first, health care technology company, today announced that a key piece of its BetterWay™ Blood Testing ecosystem has achieved 510(k) ...

For decades, diagnosing Alzheimer’s disease (AD) has required access to specialist memory clinics, neuroimaging or invasive cerebrospinal fluid (CSF) testing. That paradigm is starting to shift. In ...

FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a ...

Broad endorsement for insurance-covered blood-based CRC screening (92%) suggests payer policy could materially influence ...

A complete blood count (CBC) is a common test to diagnose anemia by measuring red blood cell count, hemoglobin, and hematocrit levels. Iron deficiency is a common cause of anemia, and doctors may ...

With the approval of anti-amyloid monoclonal antibodies to treat early-stage Alzheimer’s disease (AD), the need for accurate and early diagnosis is crucial. Blood-based biomarkers offer a promising ...